These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 20118001

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Clinical significance of dual color-dual fusion translocation fluorescence in situ hybridization in the detection of bcr/abl fusion gene.
    Wu B, Zhou S, Song L, Liu X.
    Zhonghua Zhong Liu Za Zhi; 2002 Jul; 24(4):364-6. PubMed ID: 12408765
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Cytogenetic and fluorescence in situ hybridization monitoring in Ph+ Chronic Myeloid Leukemia patients treated with imatinib mesylate.
    Fugazza G, Miglino M, Bruzzone R, Quintino S, Gatti AM, Grasso R, Gobbi M, Frassoni F, Sessarego M.
    J Exp Clin Cancer Res; 2004 Jun; 23(2):295-9. PubMed ID: 15354415
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A two-color BCR-ABL probe that greatly reduces the false positive and false negative rates for fluorescence in situ hybridization in chronic myeloid leukemia.
    Grand FH, Chase A, Iqbal S, Nguyen DX, Lewis JL, Marley SB, Davidson RJ, Goldman JM, Gordon MY.
    Genes Chromosomes Cancer; 1998 Oct; 23(2):109-15. PubMed ID: 9739013
    [Abstract] [Full Text] [Related]

  • 7. FISH for BCR-ABL on interphases of peripheral blood neutrophils but not of unselected white cells correlates with bone marrow cytogenetics in CML patients treated with imatinib.
    Reinhold U, Hennig E, Leiblein S, Niederwieser D, Deininger MW.
    Leukemia; 2003 Oct; 17(10):1925-9. PubMed ID: 14513039
    [Abstract] [Full Text] [Related]

  • 8. Chronic phase of ETV6-ABL1 positive CML responds to imatinib.
    Kawamata N, Dashti A, Lu D, Miller B, Koeffler HP, Schreck R, Moore S, Ogawa S.
    Genes Chromosomes Cancer; 2008 Oct; 47(10):919-21. PubMed ID: 18615681
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A study on the incidence of ABL gene deletion on derivative chromosome 9 in chronic myelogenous leukemia by interphase fluorescence in situ hybridization and its association with disease progression.
    Lee DS, Lee YS, Yun YS, Kim YR, Jeong SS, Lee YK, She CJ, Yoon SS, Shin HR, Kim Y, Cho HI.
    Genes Chromosomes Cancer; 2003 Jul; 37(3):291-9. PubMed ID: 12759927
    [Abstract] [Full Text] [Related]

  • 12. Down-regulation of miR-199b associated with imatinib drug resistance in 9q34.1 deleted BCR/ABL positive CML patients.
    Joshi D, Chandrakala S, Korgaonkar S, Ghosh K, Vundinti BR.
    Gene; 2014 Jun 01; 542(2):109-12. PubMed ID: 24680705
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
    Cortes J, Talpaz M, O'Brien S, Jones D, Luthra R, Shan J, Giles F, Faderl S, Verstovsek S, Garcia-Manero G, Rios MB, Kantarjian H.
    Clin Cancer Res; 2005 May 01; 11(9):3425-32. PubMed ID: 15867244
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
    Chelysheva EIu, Turkina AG, Misiurin AV, Aksenova EV, Domracheva EV, Zakharova AV, Khoroshko ND.
    Ter Arkh; 2007 May 01; 79(4):49-53. PubMed ID: 17564019
    [Abstract] [Full Text] [Related]

  • 17. Specific assessment of BCR-ABL transcript overexpression and imatinib resistance in chronic myeloid leukemia patients.
    Bianchini M, De Brasi C, Gargallo P, Gonzalez M, Bengió R, Larripa I.
    Eur J Haematol; 2009 Apr 01; 82(4):292-300. PubMed ID: 19191867
    [Abstract] [Full Text] [Related]

  • 18. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
    Wei Y, Hardling M, Olsson B, Hezaveh R, Ricksten A, Stockelberg D, Wadenvik H.
    Ann Hematol; 2006 Dec 01; 85(12):841-7. PubMed ID: 17006667
    [Abstract] [Full Text] [Related]

  • 19. Promyelocytic blast crisis of chronic myelogenous leukemia during imatinib treatment.
    Gozzetti A, Bocchia M, Calabrese S, Pirrotta MT, Crupi R, Raspadori D, Lauria F.
    Acta Haematol; 2007 Dec 01; 117(4):236-7. PubMed ID: 17308370
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.